The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 35, No. 11, pp. 1480-1484. DOI 10.1345/aph.1A004
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clarke, A.
Right arrow Articles by Miller, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clarke, A.
Right arrow Articles by Miller, S.


Research Articles

The debate regarding continuous use of oral contraceptives

AK Clarke and SJ Miller

OBJECTIVE: To determine whether oral contraceptives (OCs) can be used safely in a continuous manner to prevent monthly withdrawal bleeding. DATA SOURCES: Search of MEDLINE (1966-2000), International Pharmaceutical Abstracts (1970-2000), and the Internet. DATA SYNTHESIS: Several prospective studies have assessed the efficacy of continuous cycle OCs in preventing monthly withdrawal bleeding. Monophasic OCs are useful for this purpose. In studies using traditional OC regimens as a control, patients receiving continuously administered OCs experienced more breakthrough bleeding and spotting. Continuous use of OCs decreased headache and other menstruation-associated symptoms. No long-term trials have assessed the impact of continuous use of OCs on risk of cancer, thromboembolic disease, or fertility, concems raised by opponents of the method. CONCLUSIONS: From the data available, continuous use of OCs is an effective method for delaying withdrawal bleeding. Long-term safety data are not available.


This article has been cited by other articles:


Home page
Obstet GynecolHome page
F. H. Stewart, A. M. Kaunitz, K. D. LaGuardia, D. L. Karvois, A. C. Fisher, A. J. Friedman, and for the ORTHO EVRA Extended Regimen Study Group
Extended Use of Transdermal Norelgestromin/Ethinyl Estradiol: A Randomized Trial
Obstet. Gynecol., June 1, 2005; 105(6): 1389 - 1396.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
L. Miller and J. P. Hughes
Continuous Combination Oral Contraceptive Pills to Eliminate Withdrawal Bleeding: A Randomized Trial
Obstet. Gynecol., April 1, 2003; 101(4): 653 - 661.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.